PMA

P140023: COBAS KRAS MUTATION TEST

FDA PMA · Somatic gene mutation detection system · Roche Molecular Systems, Inc.

Key facts

PMA number P140023
Trade name COBAS KRAS MUTATION TEST
Generic name Somatic gene mutation detection system
Applicant Roche Molecular Systems, Inc.
Owner/operator Roche Diagnostics Operations Inc.
Product code OWD
Approval date May 7, 2015
Docket number 15M-1708
Notice date May 18, 2015
Establishment registration 3004141078
FEI number 1000250259

At a glance

  • 10–99 Supplements
  • Mar 17, 2026 Latest supplement decision
  • No Withdrawn
  • Yes Summary of safety and effectiveness on file
  • 1–9 UDI device identifiers (GUDID)
  • None MAUDE adverse event reports
  • None Recall events

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About PMA approvals

Premarket approval (PMA) is the FDA's most stringent review pathway, required for most Class III devices that support or sustain life or present a potentially unreasonable risk.

Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date:

Browse all PMA approvals